drugset / Trial / NCT05293028
Study of F527 in Patients With Relapsed or Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a non-randomized, open-label, phase I dose-finding and dose-expansion study to evaluate the safety, tolerability, antitumor efficacy, PK and immunogen of F527 in patients with relapsed or refractory lymphoma sexual characteristics.
Timeline
- Start
- 2022-05-20
- Primary completion
- 2023-11-20
- Completion
- 2024-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F527 | Unknown | 0.001 mg/kg | — |
| Subject | F527 | Unknown | 0.01 mg/kg | — |
| Subject | F527 | Unknown | 0.1 mg/kg | — |
| Subject | F527 | Unknown | 0.3 mg/kg | — |
| Subject | F527 | Unknown | 1 mg/kg | — |
| Subject | F527 | Unknown | 3 mg/kg | — |
| Subject | F527 | Unknown | 10 mg/kg | — |